UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549





FORM 10-Q/A


(Amendment No. 2)





þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934





For the quarterly period ended June 30, 2012





OR





o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934





For the transition period from _____ to _____





Commission file number 000-53723





IMMUNOVATIVE, INC.


(f/k/a Novo Energies Corporation)


(Exact name of registrant as specified in its charter)





Florida

65-1102237(State or other jurisdiction ofIdentification No.)

(I.R.S. Employer or organization)





39 Old Ridgebury Road


Danbury, CT  06180


(Address of principal executive offices)  (Zip Code)





(917) 796-9926


(Registrant's telephone number, including area code)





Securities registered under Section 12(b) of the Exchange Act:


None





Securities registered under Section 12(g) of the Exchange Act:


Common Stock, $.00001 Par Value





(Title of class)





Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  þ      No  o





Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  þ   Yes     o  No





Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer.  See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.





Large Accelerated Filer  o           Accelerated Filer  o            Non-Accelerated Filer  o           Smaller Reporting Company   þ





Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o  Yes    þ   No





On September 30, 2011, the last business day of the registrant’s most recently completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was $11,781,807, based upon the closing price on that date of the Common Stock of the registrant on the OTC Bulletin Board system of $0.175.  For purposes of this response, the registrant has assumed that its directors, executive officers and beneficial owners of 5% or more of its Common Stock are deemed affiliates of the registrant.





As of August 12, 2012 the registrant had 140,596,457 shares of its Common Stock, $0.00001 par value, outstanding.











Explanatory Note





The purpose of this Amendment No. 2 to Immunovative, Inc. Quarterly Report on Form 10-Q and Form 10-Q/A, Amendment No. 1, for the quarterly period ended June 30, 2012, filed with the Securities and Exchange Commission on August 14, 2012 (the “Form 10-Q”) and August 28, 2012 (the “Form 10-Q/A”), respectively, is solely to correct the cover page in regards to the line “Indicate by check mark whether the registrant is a shell company (as definable in Rule 12b-2 of the Exchange Act).”  The prior submission was missing the empty box next to the “Yes” therefore the checked box was uncertain as to the answer.  The box is checked as “No” as has previously been submitted.





No other changes have been made to the Form 10-Q or Form 10-Q/A.  This Amendment No. 2 to the Form 10-Q and Form 10-Q/A, speaks as of the original filing date of the Form 10-Q and Form 10-Q/A, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q and Form 10-Q/A.








2





ITEM 6. EXHIBITS.





Exhibit31.1

Certification of Chief Executive OfficerExhibit31.2

Certification of Chief Financial OfficerExhibit32.1

Certification of Chief Executive OfficerExhibit32.2

Certification of Chief Financial Officer








3








SIGNATURES





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.





IMMUNOVATIVE, INC.


(formerly Novo Energies Corporation)


(Registrant)





Date: November 26, 2012/s/ Seth ShawSeth ShawChief Executive Officer





Date: November 26, 2012/s/ Bruce HarmonBruce HarmonChief Financial Officer









3